Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome.

Abstract

Patients surviving an acute coronary syndrome (ACS) remain at increased risk of ischemic events long term. This paper reviews current evidence and guidelines for oral antiplatelet therapy for secondary prevention following ACS, with respect to decreased risk of ischemic events versus bleeding risk according to individual patient characteristics and risk factors. Specifically, data are reviewed from clinical studies of clopidogrel, prasugrel, ticagrelor and vorapaxar, as well as the results of systematic reviews and meta-analyses looking at the benefits and risks of oral antiplatelet therapy, and the relative merits of shorter versus longer duration of dual antiplatelet therapy, in different patient groups.

• Authors: Jeffrey S Berger
• Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions (Am J Cardiovasc Drugs) Vol. 18 Issue 6 Pg. 457-472 (Dec 2018) ISSN: 1179-187X [Electronic] New Zealand
• PMID: 29987548 (Publication Type: Journal Article, Review)

Chemical References

• Platelet Aggregation Inhibitors
• Purinergic P2Y Receptor Antagonists
• Receptor, PAR-1
• Receptors, Purinergic P2Y12
• Thromboxane A2
• Adenosine Diphosphate
• Cyclooxygenase 1
• Thrombin

Topics

• Acute Coronary Syndrome (epidemiology, prevention & control)
• Adenosine Diphosphate (metabolism)
• Administration, Oral
• Aging
• Blood Platelets (metabolism)
• Cyclooxygenase 1 (biosynthesis)
• Diabetes Mellitus (epidemiology)
• Drug Administration Schedule
• Hemorrhage (chemically induced)
• Humans
• Platelet Aggregation Inhibitors (administration & dosage, adverse effects)
• Practice Guidelines as Topic
• Purinergic P2Y Receptor Antagonists (administration & dosage, adverse effects)
• Receptor, PAR-1 (biosynthesis)
• Receptors, Purinergic P2Y12 (biosynthesis)
• Renal Insufficiency (epidemiology)
• Risk Factors
• Secondary Prevention (methods)
• Thrombin (metabolism)
• Thromboxane A2 (biosynthesis)
• Time Factors
• Vascular Diseases (epidemiology)